Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 271 to 280 of 397

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]Technology appraisal guidance
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Technology appraisal guidanceTBC
Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332Technology appraisal guidanceTBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]Technology appraisal guidanceTBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]Technology appraisal guidanceTBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All